In addition, the effectiveness of immunotherapy for NSCLC remains limited, such as the low sensitivity and specificity for PD-L1 expression, and although PD-1/PD-L1 immune checkpoint inhibitors have become the new standard of care for advanced NSCLC, immunotherapy alone has a high proportion of patients with primary nonresponse [45]. Here, CD274 is linked to non-small cell lung carcinoma.